The results of preclinical investigations highlight in particular the relationship between the manipulation of A2AR and depression and suggest that A2AR antagonists may constitute a novel strategy for the treatment of depressive disorders (Cunha 2008; Gomes et al. 2011). This evidence concerns the gene ADORA2A and depressive symptom measurement.